<DOC>
	<DOCNO>NCT02977637</DOCNO>
	<brief_summary>Magnetic resonance ( MR ) image perform contrast agent highlight blood vessel allow interpretation diagnosis blood vessel abnormality . HHT ( Hereditary Hemorrhagic Telangiectasia ) disease blood vessel , suffer fatal bleeding abnormal blood vessel detect treat early . Patients HHT also require many image study lifetimes surveillance blood vessel . Many HHT patient also co-existing iron deficiency anemia bleed nose gastrointestinal tract , receive daily iron therapy . Ferumoxytol alternative MR contrast agent , FDA ( Food Drug Administration ) approve treatment iron deficiency anemia . In addition , associate risk kidneys agent . The use ferumoxytol MR imaging may benefit patient currently receive image due contraindication conventional contrast agent . It avoid use ionize radiation . Also , conventional contrast agent associated risk . Iodinated contrast CT associate significant risk kidney damage . Another imaging technique , MR , use gadolinium base contrast agent . Gadolinium , use patient pre exist kidney dysfunction ( define GFR &lt; 30ml/min ) associate development another devastate disease call nephrogenic systemic fibrosis . As HHT patient require repeat scan throughout lifetime , study provide safe alternative . Ten patient HHT clinic use ferumoxytol MR agent clinically indicate invited participate study , determine MR ferumoxytol able detect characterize vascular malformation HHT .</brief_summary>
	<brief_title>MRA With Feraheme HHT</brief_title>
	<detailed_description>The safety use gadolinium base contrast agent MR concern FDA , risk development nephrogenic systemic fibrosis recent discovery accumulation gadolinium brain patient receive multiple prior MR scan . Hereditary hemorrhagic telangiectasia ( HHT ) manifest multiple vascular malformation ( VMs ) skin , mucous membrane solid organ affect spine , brain , liver , gastrointestinal tract , pancreas , lung . The disease autosomal dominant inheritance affect 1 5000 individual . Cerebral vascular malformation occur 23 % HHT patient , bleed risk 0.5 % per year . Pulmonary AVMs occur 15-50 % HHT patient , complication rate 50 % range fatal hemoptysis hemothorax stroke cerebral abscess . Liver vascular malformation present 32-78 % HHT patient . The rationale screen vascular malformation detection treatable lesion prior development fatal complication . The international guideline currently recommend different first line screen test organ : MRI cerebral VMs , transthoracic echocardiography pulmonary VMs , endoscopy gastrointestinal VMs , Doppler US CT liver VMs . Contrast enhance magnetic resonance angiography ( CE-MRA ) may play important role simultaneous whole body screen vascular malformation . The advantage CE-MRA include visualization entire body vasculature one examination , high spatial resolution comparable CT , ionize radiation easy multiplanar reconstruction . Substituting conventional gadolinium base contrast agent ( GBCA ) ultra small , super paramagnetic iron oxide agent ( USPIO ) e.g ferumoxytol , eliminate potential risk develop nephrogenic systemic fibrosis . Since 2009 , ferumoxytol ( 'Feraheme ' Advanced Magnetics , Cambridge , MA ) FDA approve treatment iron deficiency anemia adult patient chronic kidney disease . The result prior study suggest ferumoxytol comparable standard GBCAs CE- MRA . Our experience use ferumoxytol date suggest superior agent detection vascular malformation range vascular territory uniquely capable interrogate multiple territory one sitting , due highly stable intravascular residence time .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Definite diagnosis HHT ( clinically genetically confirm ) Known suspect AVMs brain , lung , and/or liver Use ferumoxytol MR agent clinically indicate Age &lt; 18 Unable MRI scan Prior adverse reaction ferumoxytol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hht</keyword>
	<keyword>hereditary</keyword>
	<keyword>hemorrhagic</keyword>
	<keyword>telangiectasia</keyword>
	<keyword>feraheme</keyword>
</DOC>